MedTrace Logo

Efficacy and Safety Study of ARC-4558 for Management of Pain Associated With Painful Diabetic Neuropathy

NCT00695565 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 180

Last updated 2016-11-08

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether ARC-4558 is effective in managing pain associated with painful diabetic neuropathy.

Conditions

  • Painful Diabetic Neuropathy

Interventions

DRUG

Placebo Gel

TID x 12 weeks

DRUG

Clonidine Topical Gel (ARC-4558)

TID x 12 weeks

Sponsors & Collaborators

  • Arcion Therapeutics Inc

    lead INDUSTRY

Principal Investigators

  • James N Campbell, M.D. · Arcion Therapeutics Inc

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-05-31
Primary Completion
2009-12-31
Completion
2010-02-28

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00695565 on ClinicalTrials.gov